-69.8%
UVXY vs GSK
+31.2%
-101.0%
-74.7%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 1y.
| Period | Portfolio | GSK | Excess | Alpha |
|---|---|---|---|---|
| 1D | +0.7% | -1.9% | +2.6% | -0.3% |
| 7D | -5.0% | -1.8% | -3.2% | -5.9% |
| 30D | -20.5% | -2.2% | -18.4% | -21.4% |
| 3M | -36.6% | -1.8% | -34.8% | -37.0% |
| 6M | -56.9% | -10.6% | -46.3% | -58.3% |
| YTD | -51.2% | +4.4% | -55.6% | -51.1% |
| 1Y | -69.8% | +30.4% | -100.2% | -68.2% |
| All | -69.8% | +31.2% | -101.0% | -68.2% |
Cumulative growth
Daily Returns
Daily percentage return beside GSK.
Daily Out/Under-Performance
Portfolio return minus GSK return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × GSK return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 1y: compounded portfolio wealth divided by compounded GSK wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
1y analysis · Full analysis span regression · 6 months rolling